ライフサイエンスコーパス: FTC

1 FTC resistance among those initiating PrEP with acute in

2 FTCs and constant freezing shifted nematode body size di

3 FTCs reduced both bacterial and nematode abundance, but

4 In 498 participants (247 FTC/TDF, 251 placebo), BMD in those randomized to FTC/TD

5 3TC/FTC-resistant mutants (M184V/I) emerged infrequently (7/

6 pporting the use of coformulated TDF and 3TC/FTC as preferred backbone drugs for PEP.

7 on with SHIVK65R (P = .028), although 4 of 6 FTC/TDF-treated macaques were infected at the end of the

8 elephone contact within 2 working days after FTC transmission, (2) follow-up contacts according to st

9 and (3) medical intervention initiated after FTC due to cardiac decompensation.

10 ors, but Pol gamma discriminates against (-)-FTC-TP by two orders of magnitude better than (-)-3TC-TP

11 Furthermore, although (-)-FTC-TP is only slightly more potent against HIV RT than

12 Nonetheless, 3TC and FTC (collectively referred to as XTC) appear to retain m

13 Nonetheless, 3TC and FTC (collectively referred to as XTC) appear to retain m

14 DF in DRIVE-FORWARD; and 3TC/TDF for DOR and FTC/TDF for EFV in DRIVE-AHEAD.

15 Here, we evaluate TDF and FTC in combination with the broadly neutralizing antibod

16 nd by plasma concentrations of tenofovir and FTC at week 4); and safety (clinical and laboratory adve

17 lambda-DNA-D-dCTP, L-dCTP, (-)3TC-TP, and (-)FTC-TP all have their ribose rotated by 180 degrees .

18 test, which did not differ between the arms (FTC/TDF vs placebo, P = .81).

19 2 vs placebo]), and 8.8 among those assigned FTC+TDF (incidence difference, -1.3; 95% CI, -4.1 to 1.5

20 BIC/FTC/TAF led to rapid decay of HIV-1 RNA in genital and r

21 iretroviral-naive individuals initiating BIC/FTC/TAF.

22 hormone concentrations were not affected by FTC/TDF PrEP use.

23 have been discovered, i.e., fumitremorgin C (FTC), Ko143, and the alkaloid harmine, which contain a t

24 EVG/c/FTC/TDF led to greater decreases in sCD14, hsCRP, and Lp

25 Significant differences favoring EVG/c/FTC/TDF were noted for changes in sCD14, hsCRP, and Lp-P

26 itabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that of efavirenz/emtricitabine/tenofovir

27 included random assignment to receive EVG/c/FTC/TDF, higher baseline sCD14 level, and larger decreas

28 ta are limited in follicular thyroid cancer (FTC), a PI3 kinase-driven tumor.

29 varian cancer (OC) or fallopian tube cancer (FTC).

30 a (FTA), and malignant follicular carcinoma (FTC) and papillary carcinoma (PTC) thyroid tissues.

31 Daily oral TDF (n = 598), combination FTC+TDF (n = 566), or placebo (n = 621) through July 201

32 receiving PrEP with TDF alone or combination FTC+TDF compared with placebo at conception.

33 inistration (FDA), Federal Trade Commission (FTC), state attorneys general, and US Department of Just

34 f receiving New Zealand's Family Tax Credit (FTC) and self-rated health (SRH) in 6,900 working-age pa

35 trathoracic fluid index threshold crossings (FTC) were low indicating physicians' inappropriate react

36 in increased warming and freeze-thaw cycle (FTC) frequency pose great ecological challenges to organ

37 DBS after 4 weeks of directly observed daily FTC/TDF PrEP use.

38 ave sex with men (MSM) to receive oral daily FTC/TDF or placebo.

39 BS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP (r = 0.587; P < .001).

40 DTG + FTC was non-inferior to cART.

41 Non-inferiority of DTG + FTC versus cART for viral suppression was assessed using

42 he 48-week efficacy and safety data on DTG + FTC versus cART.

43 In this study, DTG + FTC as maintenance therapy was non-inferior to cART in t

44 in the cART arm (16%) compared to the DTG + FTC arm (6.5%) (p = 0.041), but none was considered to b

45 /ml) through 48 weeks was 93.5% in the DTG + FTC arm and 94.7% in the cART arm in the intention-to-tr

46 thm, 84/93 (90.3%) participants in the DTG + FTC arm had an HIV-1 RNA viral load of <50 copies/ml com

47 re between baseline and week 48 in the DTG + FTC compared to the cART arm (adjusted difference +2.6;

48 RT were randomized 1:1 to switching to DTG + FTC or to continuing cART, and 1:1 to simplified patient

49 -three participants were randomized to DTG + FTC, and 94 individuals to cART.

50 cantly different between DOR/3TC/TDF and EFV/FTC/TDF (-1.6 vs +8.7 mg/dL and -3.8 vs +13.3 mg/dL, res

51 s/mm3 for DRV+r, and 188.4 cells/mm3 for EFV/FTC/TDF.

52 icitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

53 ricitabine at 200 mg, and TDF at 300 mg (EFV/FTC/TDF) for 96 weeks.

54 TC/TDF recipients and 80.8% (294/364) of EFV/FTC/TDF recipients achieved <50 HIV-1 RNA copies/mL (dif

55 ly) with FTC/TDF or ABC/3TC (n = 383) or EFV/FTC/TDF (600/200/300 mg daily; n = 364).

56 nd altered sensorium (4.4% vs 8.2%) than EFV/FTC/TDF recipients.

57 DF demonstrated non-inferior efficacy to EFV/FTC/TDF at week 48 and was well tolerated, with signific

58 hsCRP, and Lp-PLA2 levels, compared with EFV/FTC/TDF.

59 ges in LDL-C and non-HDL-C compared with EFV/FTC/TDF.

60 disoproxil fumarate (TDF) and emtricitabine (FTC) are effective in HIV-1 pre-exposure prophylaxis (Pr

61 or the combination of TAF and emtricitabine (FTC) can prevent vaginal infection.

62 er the combination of TAF and emtricitabine (FTC) could prevent simian/human immunodeficiency virus (

63 nofovir alafenamide (TAF) and emtricitabine (FTC) loaded nanoparticles (NPs) to solution in humanized

64 disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before and after sexual activity.

65 gh-level lamivudine (3TC) and emtricitabine (FTC) resistance and increased tenofovir disoproxil fumar

66 gh-level lamivudine (3TC) and emtricitabine (FTC) resistance, and increased tenofovir (TDF) susceptib

67 enofovir difumarate (TDF) and emtricitabine (FTC), the quad pill includes cobicistat (COBI; an inacti

68 ce and safety of coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumara

69 < .001), as were hair TFV/DBS emtricitabine (FTC) triphosphate (TP) (r = 0.781; P < .001); hair FTC/D

70 apy (cART) switching to DTG + emtricitabine (FTC).

71 oproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg among adults living with human immunodeficie

72 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-F

73 ulated with the lipid-neutral emtricitabine (FTC), has a lipid-lowering effect.

74 ranscriptase inhibitor (NRTI) emtricitabine (FTC), and injectable aqueous nanodispersions; in vitro t

75 triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF

76 n = 141) or a combination of emtricitabine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF).

77 prophylactic efficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

78 regimens: MVC alone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and

79 vir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/la

80 vir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a viral load (VL) <50 copies/mL swi

81 In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in human immunodefic

82 fovir (TDF), coformulated TDF/emtricitabine (FTC), or placebo.

83 daily oral TDF, alone or with emtricitabine (FTC), in HIV-uninfected African men and women.

84 alone or in combination with emtricitabine (FTC-TDF) reduces the risk for HIV-1 acquisition.

85 (TDF), alone or combined with emtricitabine (FTC-TDF), compared with placebo.

86 lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) provide little structural evidence to suggest th

87 lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP) with four ternary complexes per asymmetric unit.

88 lamivudine ((-)3TC-TP) and emtricitabine ((-)FTC-TP), we structurally reveal the correct sequence of

89 r the TDF-based regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.1%; 95% CI, 43.6%-9

90 omen on ART (tenofovir [TFV], emtricitabine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppr

91 F] or DOR [100 mg daily] with emtricitabine [FTC]/TDF or abacavir [ABC]/3TC [n = 747]) compared with

92 f treatment with TDF (n552) or emtricitabine(FTC)/TDF (n57).

93 otent against HIV RT than its enantiomer (+)-FTC-TP, it is discriminated by human Pol gamma four orde

94 ave been contacted appropriately after every FTC, in 243 patients (68.3%; n=356) at least one FTC was

95 Biodistribution studies showed that (18)F-FTC-146 accumulated in S1R-rich rat organs, including th

96 ministration, significantly attenuated (18)F-FTC-146 accumulation in all rat brain regions by approxi

97 gested radioligand metabolism, whereas (18)F-FTC-146 appeared to be stable in human serum.

98 The potential of (18)F-FTC-146 as an imaging agent for a variety of neuroinflam

99 ain information about the potential of (18)F-FTC-146 for eventual clinical translation.

100 liver microsome studies revealed that (18)F-FTC-146 has a longer half-life in human microsomes, comp

101 y results demonstrated accumulation of (18)F-FTC-146 in rat brain regions known to contain S1Rs and t

102 The distribution and stability of (18)F-FTC-146 in rats were assessed via PET/CT, autoradiograph

103 tudy was to assess the S1R radiotracer (18)F-FTC-146 in rats.

104 demonstrated specific accumulation of (18)F-FTC-146 in the brain (mainly in cortical structures, cer

105 Ex vivo analysis of (18)F-FTC-146 in the brain showed that only intact radiotracer

106 Together, these results indicate that (18)F-FTC-146 is a promising tool for visualizing S1Rs in prec

107 Injection of (18)F-FTC-146 is safe, and absorbed doses are acceptable.

108 onducted along with HPLC assessment of (18)F-FTC-146 stability in monkey plasma and human serum.

109 , whereas rapid metabolism of residual (18)F-FTC-146 was observed in rat plasma.

110 High accumulation of (18)F-FTC-146 was observed in sigma-1 receptor-dense organs su

111 tion well, and no adverse reactions to (18)F-FTC-146 were reported.

112 t-in-human studies with clinical-grade (18)F-FTC-146 were successful.

113 -1-yl)ethyl)benzo[d]thiazol-2(3H)-one ((18)F-FTC-146).

114 y loss (52 of 143 pregnancies) was 37.5% for FTC+TDF and 36.7% for TDF alone (difference, 0.8%; 95% C

115 e, the frequency of tubulopathy was 1.7% for FTC-TDF versus 1.3% for placebo (odds ratio, 1.30; 95% c

116 for those receiving placebo (difference for FTC+TDF vs placebo, 10.2%; 95% CI, -5.3% to 25.7%; P = .

117 oviral concentration ratios were highest for FTC (11.9, 95% confidence interval [CI], 8.66-16.3), the

118 udy arms (7.8 cases per 100 person-years for FTC/TDF vs 6.8 cases per 100 person-years for placebo, P

119 Formylthiocholine (FTC) was synthesized and found to be a substrate for non

120 emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of human immunod

121 icitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects agai

122 icitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of human immunodeficiency vi

123 emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in P007; abacavir/lamivudine (ABC/3TC) or FTC/T

124 citabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone reduces the risk of human immunode

125 oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

126 icitabine and tenofovir disoproxil fumarate (FTC/TDF).

127 ir FTC/DBS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP (r = 0.587; P < .001).

128 riphosphate (TP) (r = 0.781; P < .001); hair FTC/DBS TFV-DP (r = 0.74; P < .001); hair FTC/DBS FTC-TP

129 Infection in FTC/TAF but not TAF-treated macaques was delayed relativ

130 sion of follicular thyroid cancer cell line, FTC-133 cells.

131 added emtricitabine 200 mg/tenofovir 300 mg (FTC/TDF) once daily.

132 bine (FTC, 200 mg; n = 139) and TDF (300 mg, FTC/TDF).

133 adverse events occurred in 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates d

134 value, and negative predictive value for OC/FTC detection within 1 year were 94.7% (CI, 74.0% to 99.

135 the total 19 diagnoses were stage I to II OC/FTC (CI, 28.9% to 75.6%).

136 n of 88 days before detection of incident OC/FTC.

137 een patients were diagnosed with invasive OC/FTC within 1 year of prior screening (13 diagnoses were

138 ds Women whose estimated lifetime risk of OC/FTC was >/= 10% were recruited at 42 centers in the Unit

139 ng is an option for women at high risk of OC/FTC who defer or decline RRSO, given its high sensitivit

140 nded to rebound following discontinuation of FTC/TDF.

141 Animals received clinical doses of FTC/TAF (n = 6) or TAF (n = 9) orally 24 hours before an

142 We report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with

143 The effect of FTC/TDF on incident syphilis and HIV acquisition was ass

144 The calculated efficacy of FTC/TAF and TAF was 91% (95% confidence interval [CI], 3

145 r results support the clinical evaluation of FTC/TAF for PrEP in women.

146 esults support the clinical investigation of FTC/TAF for PrEP.

147 A single-tablet regimen of FTC-RPV-TDF was well tolerated as once-daily PEP, with h

148 Similar to reports of FTC-TP, 3TC-TP exposure was significantly greater than T

149 d, double-blind, placebo-controlled trial of FTC/TDF PrEP.

150 Within the largest randomized trial of FTC/TDF versus TDF as PrEP, plasma samples were tested f

151 We predict that higher occurrence of FTCs in cold ecosystems will select for large body size

152 , this work illuminates the mechanism of (-)-FTC-TP differential selectivity and provides a structura

153 o baseline (23/52 [44%] on TDF, 4/7 [57%] on FTC/TDF).

154 Fewer subjects on FTC/TDF experienced VF (3 vs 11; P = .034).

155 In the RM group, at least one FTC alert was transmitted in 356 patients (70.5%; n=505)

156 in 243 patients (68.3%; n=356) at least one FTC was not responded by an appropriate contact.

157 F) in P007; abacavir/lamivudine (ABC/3TC) or FTC/TDF in DRIVE-FORWARD; and 3TC/TDF for DOR and FTC/TD

158 rettes smoked under ISO (Cambridge Filter or FTC) and Intense (Health Canada or Canadian Intense) con

159 k for up to 16 weeks and received placebo or FTC/TDF pericoitally.

160 ek for up to 19 weeks and received saline or FTC/TAF 24 hours before and 2 hours after each virus ino

161 o HSV-2 (79 of 1041 assigned to tenofovir or FTC-TDF PrEP [HSV-2 incidence, 5.6 per 100 person-years]

162 Oral FTC/TDF maintains efficacy in a macaque model of sexuall

163 Daily oral FTC-TDF PrEP was not significantly associated with tubul

164 ilar for the intermittent gel and daily oral FTC/TDF regimens, but lower for the daily gel regimen.

165 eekly in the event of no RAI), or daily oral FTC/TDF.

166 In HIV-uninfected persons, FTC/TDF PrEP was associated with small but statistically

167 inferior to RTV in combination with ATV plus FTC/TDF at week 48.

168 ovir disoproxil fumarate (TDF), and TDF plus FTC.

169 Of 121 HIV seroconverters, 25 received FTC/TDF, 38 received TDF, and 58 received placebo.

170 Of 1549 persons studied (776 receiving FTC-TDF, 773 receiving placebo), 64% were male, and the

171 8 pregnancies) was 42.5% for women receiving FTC+TDF compared with 32.3% for those receiving placebo

172 c thyroid cancer that most closely resembles FTC.

173 As a result, (-)-FTC is a much less toxic NRTI.

174 nfections randomized to FTC/TDF, none showed FTC/TDF mutations by clinical assays despite detectable

175 Drug resistance was rare in iPrEx on-study FTC/TDF-randomized seroconverters, and only as low-frequ

176 requiring 3-drug PEP received single-tablet FTC-RPV-TDF once daily for 28 days.

177 TAF + FTC NPs and TAF + FTC solution (each drug at 200 mg/kg)

178 By 21 days PT, 100% TAF + FTC solution-treated and control-untreated mice were inf

179 fficacy, thus establishing long-acting TAF + FTC NPs as a potential PrEP modality.

180 etectable TAF/FTC vaginal levels among TAF + FTC NP-treated hu-BLT mice correlating with prolonged Pr

181 TAF + FTC NPs and TAF + FTC solution (each drug at 200 mg/kg) were administered

182 However, TAF + FTC NPs resulted in significant (p = .0002) protection f

183 icitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were es

184 of-concept study demonstrated detectable TAF/FTC vaginal levels among TAF + FTC NP-treated hu-BLT mic

185 , 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FT

186 safe and well tolerated compared with TDF + FTC; this study was not powered for efficacy.

187 gravir [RAL], 74.7%; 95% CI, 41.4%-100%; TDF+FTC+ boosted darunavir [DRV/r], 93.9%; 95% CI, 90.2%-97.

188 vir [LPV/r], 71.1%; 95% CI, 43.6%-98.6%; TDF+FTC+raltegravir [RAL], 74.7%; 95% CI, 41.4%-100%; TDF+FT

189 o adverse drug reactions were lowest for TDF+FTC+RAL (1.9%; 95% CI, 0%-3.8%) and highest for ZDV+3TC+

190 [41.7%]; ARR, 1.15; 95% CI, 1.04-1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231

191 Of the $1638 in total payments per 30 TDF-FTC tablets in 2018, OOP payments accounted for $94 (5.7

192 Third-party and OOP payments per 30 TDF-FTC tablets increased annually.

193 period, the average total payment for 30 TDF-FTC tablets increased from $1350 to $1638 (5.0% compound

194 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8 (TDF-FTC) participants; rates did not differ among regimens.

195 tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

196 infants exposed to ART from conception, TDF-FTC-EFV was associated with a lower risk for adverse bir

197 fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472 [36.4%]) compared with TDF-FTC and

198 me to viral suppression than did the EFV-TDF-FTC group (28 vs. 84 days, P<0.001), as well as greater

199 in the DTG-ABC-3TC group than in the EFV-TDF-FTC group (88% vs. 81%, P=0.003), thus meeting the crite

200 r disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure prophylaxis (PrEP) is an effective

201 ate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure p

202 The use of TDF-FTC before and after sexual activity provided protection

203 articipants took a median of 15 pills of TDF-FTC or placebo per month (P=0.57).

204 st the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group).

205 ipants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1

206 in the proportion of persons prescribed TDF-FTC for PrEP during the study period, with 417 users in

207 ons aged >/=16 years who were prescribed TDF-FTC for PrEP each year.

208 -1.27); TDF-FTC and lopinavir-ritonavir (TDF-FTC-LPV-R) (112 of 231 [48.5%]; ARR, 1.31; 95% CI, 1.13-

209 ipants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively.

210 ions occurred during follow-up, 2 in the TDF-FTC group (incidence, 0.91 per 100 person-years) and 14

211 HIV infection were enrolled (199 in the TDF-FTC group and 201 in the placebo group).

212 rson-years), a relative reduction in the TDF-FTC group of 86% (95% confidence interval, 40 to 98; P=0

213 In the TDF-FTC group, as compared with the placebo group, there wer

214 Vaginal administration of the TDF-FTC-VRC01-N combination holds significant promise for HI

215 interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5

216 EFV) (901 of 2472 [36.4%]) compared with TDF-FTC and nevirapine (NVP) (317 of 760 [41.7%]; ARR, 1.15;

217 re safe and well-tolerated compared with TDF-FTC in U.S. women.

218 Compared with TDF-FTC-EFV, all other regimens were associated with higher

219 In arm 1, TDF/FTC was added for 12 weeks, followed by 12 weeks of plac

220 tion (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.15, 95% CI: 0.04, 0.52); and 3) in per-protoc

221 ysis (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.16, 95% CI: 0.05, 0.53).

222 5% confidence interval (CI): 0.07, 0.56; TDF/FTC HR = 0.12, 95% CI: 0.03, 0.52); 2) with IPC weights

223 in a behavioral intervention and accept TDF/FTC as PrEP.

224 content decreased within the ABC/3TC and TDF/FTC groups (combining EFV and ATV/r arms; median change,

225 Differences between the ABC/3TC and TDF/FTC groups were significant for complex I (P = .03).

226 ABC/3TC and TDF/FTC significantly and similarly decreased fat mtDNA cont

227 of participants enrolled in the Botswana TDF/FTC Oral HIV Prophylaxis Trial, the Bangkok Tenofovir St

228 or 12 weeks (placebo period) followed by TDF/FTC for 12 weeks and placebo for 12 additional weeks (wa

229 Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attri

230 ts were randomized to receive controlled TDF/FTC dosing as (1) "perfect" adherence (daily); (2) "mode

231 ntervention and were provided with daily TDF/FTC as PrEP for 48 weeks.

232 posure prophylaxis]) of 30 days of daily TDF/FTC followed by 30 days off drug were evaluated.

233 of the ANRS IPERGAY trial with on demand TDF/FTC for HIV prevention and the impact of doxycycline pos

234 r NNRTI and a backbone containing either TDF/FTC or ABC/3TC.

235 r disoproxil fumarate and emtricitabine (TDF/FTC) co-formulate for use in pre-exposure prophylaxis (P

236 fovir disoproxil fumarate/emtricitabine (TDF/FTC) doses required to achieve and maintain (after disco

237 fovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults.

238 ne (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) in 1857 human immunodeficiency virus type 1-infecte

239 h a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC).

240 e randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritona

241 fovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritona

242 fovir disoproxil fumarate-emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritona

243 acy estimates of 67% for TDF and 75% for TDF/FTC.

244 ervention in conjunction with open-label TDF/FTC.

245 fety, tolerability, and acceptability of TDF/FTC and patterns of use, rates of adherence, and pattern

246 s support the short-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest that

247 A backbone of TDF/FTC was received by 67% of PI users and 69% of NNRTI use

248 ly decreased fat mtDNA content, but only TDF/FTC decreased complex I and complex IV activity levels.

249 HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitali

250 No patient receiving TDF/FTC was admitted to the ICU or died.

251 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3

252 provide additional safety data regarding TDF/FTC use among young MSM who had negative test results fo

253 Exposure to TDF/FTC reduced TC from 234 to 205 mg/dL (P < .001), LDL-c f

254 iral load (VL) <50 copies/mL switched to TDF/FTC/EFV400.

255 After 12 weeks, TDF/FTC exposure was associated with lower TC and LDL-c leve

256 triglyceride levels did not change with TDF/FTC exposure.

257 With TDF/FTC use, no clear association was found among PI users (

258 t-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat were f

259 (32%) safety risk compared to men; with TDF/FTC, the safety risk was 20% larger for women compared t

260 ) trial and whether emtricitabine/tenofovir (FTC/TDF) modified that association.

261 Hair TFV/FTC concentrations correlate strongly with DBS levels, w

262 rders of magnitude more efficiently than (+)-FTC-TP.

263 and in PrEP breakthrough infections and that FTC is associated with a greater frequency of resistance

264 The FTC has acted against misleading marketing by a single f

265 Five of the 6 animals in the FTC/TAF and 4 of the 9 animals in the TAF alone group we

266 fection, resistance was more frequent in the FTC/TDF arm (4 of 7 [57%]), compared with the TDF arm (1

267 d in both arms with a larger decrease in the FTC/TDF arm.

268 f patients in the TDF group and 86.3% in the FTC/TDF group had levels of HBV DNA <69 IU/mL (P = .43).

269 between groups; only 1 patient (0.7%) in the FTC/TDF group lost hepatitis B surface antigen.

270 Of all participants, 5.1%-6.8% received the FTC for 1-3 years and 1.8%-3.6% for 4-7 years.

271 Cumulatively receiving the FTC marginally reduced SRH.

272 lyses, each additional year of receiving the FTC was associated with 0.033 (95% confidence interval (

273 arm (1 of 19 [5.3%]; P = .01), owing to the FTC-associated mutation M184IV.

274 for interaction between randomization to the FTC/TDF arm and incident syphilis on HIV incidence.

275 )-2,3'-dideoxy-5-fluoro-3'-thiacytidine, (-)-FTC] and lamivudine, [(-)-2,3'-dideoxy-3'-thiacytidine,

276 daily gel use for HIV protection compared to FTC/TDF (OR, 0.38; P < .001).

277 or RAI gel (IRR, 0.90; P = .51) compared to FTC/TDF.

278 usual care, RM with appropriate contacts to FTC alerts independently reduced the risk of the primary

279 d appropriate from inappropriate contacts to FTC transmissions in the OptiLink HF trial (Optimization

280 ose with acute infection at randomization to FTC/TDF, M184V or I mutations that were predominant at s

281 DF, 251 placebo), BMD in those randomized to FTC/TDF decreased modestly but statistically significant

282 Two randomized to FTC/TDF had minor variant M184I detected at 0.53% by AS-

283 Of the 48 on-study infections randomized to FTC/TDF, none showed FTC/TDF mutations by clinical assay

284 were measured in participants randomized to FTC/TDF.

285 h was detected in 53% of those randomized to FTC/TDF.

286 RM appropriate reactions to FTC alerts are associated with significantly improved cl

287 tection against vaginal challenge similar to FTC/TFV disoproxil fumarate combination in the macaque m

288 57 patients (10%)were eligible to switch to FTC/TDF; the majority had HBV DNA <400 copies/mL at thei

289 visit regardless of whether they switched to FTC/TDF (n534) or maintained TDF monotherapy (n517).

290 Switching to FTC/TDF showed improved NCEP thresholds for TC and TG an

291 evaluate efficacy and safety of switching to FTC/TDF.

292 note, only 55.5% (n=758) of all transmitted FTCs (n=1365) were followed by an appropriate contact.

293 ate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in the FGT have been previously described.

294 thyroid versus PTC and benign thyroid versus FTC, were built and validated with 114,125 mass spectra,

295 IV with resistance mutations associated with FTC (K65R and M184IV) and TDF (K65R and K70E), using 454

296 compared with DRV+r (800/100 mg daily) with FTC/TDF or ABC/3TC (n = 383) or EFV/FTC/TDF (600/200/300

297 0%-85% maintained levels <400 copies/mL with FTC/TDF intensification as needed.

298 Minor variants with FTC/TDF mutations K65R, K70E, M184V/I were measured usin

299 LPV/r monotherapy after first-line VF with FTC/TDF intensification when needed provides durable sup

300 In contrast, warm temperatures without FTCs could lead to divergent responses in soil bacteria